Literature DB >> 23832932

Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Stuart Ibsen1, Yongxuan Su, John Norton, Eran Zahavy, Tomoko Hayashi, Stephen Adams, Wolf Wrasidlo, Sadik Esener.   

Abstract

The localized conversion of inactive doxorubicin prodrug chemotherapeutics to pharmacalogically active forms is difficult to quantify in mouse tumor models because it occurs only in small regions of tissue. The tumor tissue extraction protocol and LC-MS/MS analysis method described here were optimized to obtain a detection limit of 7.8 pg for the activated doxorubicin and 0.36 ng for the doxorubicin prodrug. This method can be useful for determining the biodistribution and activation efficiency for many different doxorubicin prodrugs. It can also be used for quantification of doxorubicin from tumor models that have poor vascularization resulting in low tissue accumulation.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  LC-MS/MS; doxorubicin; prodrug; tissue extraction

Mesh:

Substances:

Year:  2013        PMID: 23832932      PMCID: PMC4110111          DOI: 10.1002/jms.3221

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  27 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Authors:  Robert D Arnold; Jeanine E Slack; Robert M Straubinger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-05       Impact factor: 3.205

3.  The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.

Authors:  K Breistøl; H R Hendriks; D P Berger; S P Langdon; H H Fiebig; O Fodstad
Journal:  Eur J Cancer       Date:  1998-09       Impact factor: 9.162

4.  Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue.

Authors:  T E Mürdter; B Sperker; K Bosslet; P Fritz; H K Kroemer
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-05-29

Review 5.  Doxorubicin-induced cardiomyopathy.

Authors:  P K Singal; N Iliskovic
Journal:  N Engl J Med       Date:  1998-09-24       Impact factor: 91.245

Review 6.  Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.

Authors:  R D Olson; P S Mushlin
Journal:  FASEB J       Date:  1990-10       Impact factor: 5.191

7.  High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues.

Authors:  L Alvarez-Cedrón; M L Sayalero; J M Lanao
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-01-22

8.  Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.

Authors:  M S Ewer; N Jaffe; H Ried; H A Zietz; R S Benjamin
Journal:  Med Pediatr Oncol       Date:  1998-12

9.  Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection.

Authors:  J de Jong; W S Guérand; P R Schoofs; A Bast; W J van der Vijgh
Journal:  J Chromatogr       Date:  1991-09-18

10.  Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs.

Authors:  L F Tietze; M Neumann; T Möllers; R Fischer; K H Glüsenkamp; M F Rajewsky; E Jähde
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

View more
  4 in total

1.  Longer heating duration increases localized doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin.

Authors:  Chenchen Bing; Pratik Patel; Robert M Staruch; Sumbul Shaikh; Joris Nofiele; Michelle Wodzak Staruch; Debra Szczepanski; Noelle S Williams; Theodore Laetsch; Rajiv Chopra
Journal:  Int J Hyperthermia       Date:  2018-12-12       Impact factor: 3.914

2.  Simple and rapid monitoring of doxorubicin using streptavidin-modified microparticle-based time-resolved fluorescence immunoassay.

Authors:  Junyu Liang; Zhigao Zhang; Hui Zhao; Shanhe Wan; Xiangming Zhai; Jianwei Zhou; Rongliang Liang; Qiaoting Deng; Yingsong Wu; Guanfeng Lin
Journal:  RSC Adv       Date:  2018-04-25       Impact factor: 4.036

3.  Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker.

Authors:  Seung Woo Chung; Jeong Uk Choi; Young Seok Cho; Ha Rin Kim; Tae Hyung Won; Peter Dimitrion; Ok-Cheol Jeon; Seong Who Kim; In-San Kim; Sang Yoon Kim; Youngro Byun
Journal:  Adv Sci (Weinh)       Date:  2018-06-05       Impact factor: 16.806

4.  Optoacoustic properties of Doxorubicin - A pilot study.

Authors:  Melanie A Kimm; Claudia Gross; Xose Luis Déan-Ben; Avihai Ron; Ernst J Rummeny; Hsiao-Chun Amy Lin; Carsten Höltke; Daniel Razansky; Moritz Wildgruber
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.